ETBX-021

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameETBX-021
Drug Alias NameAd5 [E1-, E2b-]-HER2/neu VaccineETBX-021
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulantsReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsProstatic NeoplasmsCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEtubics CorpNantbioscience Inc
China Registration ClassN/A

Develop Information

Active CompaniesWashington University School Of Medicine
Inactive CompaniesImmunitybio IncNantbioscience Inc
Active IndicationsProstatic Neoplasms
Inactive IndicationsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsPancreatic Neoplasms +[7] 

Other Information

ATC CodeN/A
Related LinksN/A